Grace Therapeutics, Inc. financial data

Symbol
GRCE on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 March
Latest financial report
10-Q - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1177% % 45%
Debt-to-equity 7.4% % -58%
Return On Equity -9.3% % 60%
Return On Assets -8.6% % 56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,474,026 shares 15%
Common Stock, Shares, Outstanding 15,474,026 shares 53%
Entity Public Float $24,040,390 USD 36%
Weighted Average Number of Shares Outstanding, Basic 16,933,620 shares 47%
Weighted Average Number of Shares Outstanding, Diluted 16,933,620 shares 47%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,618,000 USD -62%
Selling and Marketing Expense $252,000 USD -62%
General and Administrative Expense $7,631,000 USD 6%
Operating Income (Loss) $11,249,000 USD 33%
Nonoperating Income (Expense) $4,252,000 USD 1225%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,997,000 USD 57%
Income Tax Expense (Benefit) $1,018,000 USD 67%
Net Income (Loss) Attributable to Parent $5,979,000 USD 55%
Earnings Per Share, Basic -0.3 USD/shares 72%
Earnings Per Share, Diluted -0.3 USD/shares 72%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $18,672,000 USD 69%
Accounts Receivable, after Allowance for Credit Loss, Current $398,000 USD -52%
Assets, Current $19,211,000 USD 61%
Property, Plant and Equipment, Net $15,000 USD -38%
Operating Lease, Right-of-Use Asset $0 USD -100%
Intangible Assets, Net (Excluding Goodwill) $41,128,000 USD 0%
Goodwill $8,138,000 USD 0%
Assets $68,488,000 USD 12%
Employee-related Liabilities, Current $550,000 USD 12%
Accrued Liabilities, Current $814,000 USD -18%
Liabilities, Current $1,284,000 USD -35%
Deferred Income Tax Liabilities, Net $2,312,000 USD -31%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $3,596,000 USD -60%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,038,000 USD 0%
Retained Earnings (Accumulated Deficit) $227,302,000 USD -2.7%
Stockholders' Equity Attributable to Parent $64,892,000 USD 24%
Liabilities and Equity $68,488,000 USD 12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,801,000 USD 50%
Net Cash Provided by (Used in) Financing Activities $327,000 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 15,474,026 shares 53%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,128,000 USD 41%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18,672,000 USD 69%
Deferred Tax Assets, Valuation Allowance $49,530,000 USD 4.8%
Deferred Tax Assets, Gross $58,779,000 USD 11%
Operating Lease, Liability $0 USD -100%
Depreciation $2,000 USD 100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,979,000 USD 55%
Property, Plant and Equipment, Gross $26,000 USD -96%
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.043 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD
Deferred Tax Assets, Operating Loss Carryforwards $43,049,000 USD 5.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $298,231,000 USD 6.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $9,249,000 USD 58%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%